Beth Israel Deaconess Medical Center: Behind the Approvals - Decades of Translational Research Leads to a New Generation of Targeted Therapies
December 21, 2023
December 21, 2023
BOSTON, Massachusetts, Dec. 21 (TNSres) -- Beth Israel Deaconess Medical Center issued the following Q&A on Dec. 20, 2023, with Alex Toker, professor in the Department of Pathology:
* * *
Last month, the U.S. Food and Drug Administration (FDA) approved the use of the drug capivasertib, in combination with a current cancer treatment called fulvestrant for patients with the most common type of breast cancer, the HR-positive/HER2-negative subtype. Known as an AKT inhib . . .
* * *
Last month, the U.S. Food and Drug Administration (FDA) approved the use of the drug capivasertib, in combination with a current cancer treatment called fulvestrant for patients with the most common type of breast cancer, the HR-positive/HER2-negative subtype. Known as an AKT inhib . . .